文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

肝功能衰竭的病因及相关临床指标:无锡肝功能衰竭定点医院3年病例数据分析

[Etiology and related clinical indicators of liver failure: an analysis of 3-year case data of Wuxi designated hospital for treatment of liver failure].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2022-01-01
一句话结论HBV是肝功能衰竭主要病因,HBV相关者更年轻、ICU住院更长,合并肝癌是死亡主要因素,AT III有反映疾病结局的潜在价值。

该研究回顾性分析2018年1月至2020年12月无锡市第五人民医院(肝功能衰竭定点医院)ICU收治的369例肝功能衰竭患者,按《肝功能衰竭诊治指南(2018年版)》分为非HBV相关134例(36.3%)和HBV相关235例(63.7%)。HBV相关肝功能衰竭男性为女性的4.34倍(191例 vs. 44例),高于非HBV相关者的1.03倍(68例 vs. 66例)。出院后6个月随访显示,HBV相关肝功能衰竭死亡患者中男性占78.76%、存活患者中男性占92.86%(均P<0.01);非HBV相关组死亡患者年龄高于存活患者(58.53±0.15岁 vs. 54.38±3.01岁,P<0.05),AT III水平低于存活患者[(32.20±6.43)% vs.(38.63±2.74)%,P<0.05]。HBV相关肝功能衰竭死亡组ICU住院时间短于存活组(23.77±11.74天 vs. 35.51±2.85天,P<0.01)。HBV相关肝功能衰竭合并肝癌者出院后6个月病死率高于非HBV相关肝功能衰竭(12.34% vs. 2.24%,P<0.01)。

要点

  • HBV是肝功能衰竭主要病因:369例中HBV相关235例(63.7%),非HBV相关134例(36.3%)。
  • HBV相关肝功能衰竭男性为女性的4.34倍(191例 vs. 44例),高于非HBV相关的1.03倍(68例 vs. 66例)。
  • 非HBV相关肝功能衰竭死亡患者年龄高于存活患者(58.53±0.15岁 vs. 54.38±3.01岁,P<0.05),AT III低于存活患者[(32.20±6.43)% vs.(38.63±2.74)%,P<0.05]。
  • HBV相关肝功能衰竭死亡组ICU住院时间短于存活组(23.77±11.74天 vs. 35.51±2.85天,P<0.01)。
  • HBV相关肝功能衰竭合并肝癌者出院后6个月病死率高于非HBV相关肝功能衰竭(12.34% vs. 2.24%,P<0.01)。

适用人群与场景

  • 2018年1月至2020年12月无锡市第五人民医院(肝功能衰竭定点医院)ICU收治的369例肝功能衰竭患者。
  • 按《肝功能衰竭诊治指南(2018年版)》分为非HBV相关肝功能衰竭134例(36.3%)和HBV相关肝功能衰竭235例(63.7%)。

诊断标准与关键阈值

  • 病因分类依据《肝功能衰竭诊治指南(2018年版)》。

研究设计与关键结果

  • 研究类型:回顾性分析;样本量369例;单中心(无锡市第五人民医院ICU);人群为肝功能衰竭患者。
  • HBV相关肝功能衰竭男性为女性的4.34倍(191例 vs. 44例),高于非HBV相关肝功能衰竭的1.03倍(68例 vs. 66例)。
  • 出院后6个月随访:HBV相关肝功能衰竭死亡患者中男性占78.76%、女性占21.24%(P<0.01);存活患者中男性占92.86%、女性占7.14%(P<0.01)。
  • 非HBV相关肝功能衰竭死亡患者年龄高于存活患者(58.53±0.15岁 vs. 54.38±3.01岁,P<0.05),AT III水平低于存活患者[(32.20±6.43)% vs.(38.63±2.74)%,P<0.05]。
  • HBV相关肝功能衰竭死亡组ICU住院时间短于存活组(23.77±11.74天 vs. 35.51±2.85天,P<0.01)。
  • HBV相关肝功能衰竭合并肝癌者出院后6个月病死率高于非HBV相关肝功能衰竭(12.34% vs. 2.24%,P<0.01)。
  • 接受人工肝治疗、合并肝性脑病及肝硬化患者的出院后6个月病死率在不同类型肝功能衰竭组间无显著差异。

证据类型、等级与局限

  • 证据类型:回顾性病例分析;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,HBV是肝功能衰竭的主要病因;HBV相关肝功能衰竭患者较年轻、住院时间较长,有利于疾病恢复;HBV相关肝功能衰竭合并肝癌是死亡的主要因素;AT III具有反映疾病结局的潜在价值。

指南或共识出处

  • 《肝功能衰竭诊治指南(2018年版)》

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To analyze the characteristics of etiology and clinical indicators of hepatitis B virus (HBV) and non-HBV liver failure, and to evaluate their potential roles in reflecting disease outcomes.

METHODS: The clinical data of 369 patients with liver failure admitted to the intensive care unit (ICU) of the Fifth People's Hospital of Wuxi which was the designated hospital for treatment of liver failure from January 2018 to December 2020 were retrospectively analyzed. The classification and comparison of etiology of non-HBV and HBV liver failure patients were performed according to the Guidelines on the Diagnosis and Treatment of Liver Failure (2018 edition). The indicators of liver failure related etiologies, including gender, age, anticoagulant enzyme III (AT III), total bilirubin (TBil), length of ICU stay, hepatic encephalopathy, underlying disease (liver cirrhosis and liver cancer, etc.) and usage of artificial liver were analyzed. According to the 6-month follow-up results after discharge, the differences in the etiological indicators of died and survival patients and the outcome of patients with different types of liver failure were analyzed.

RESULTS: A total of 369 patients were enrolled, including 134 (36.3%) with liver failure not caused by HBV and 235 (63.7%) with liver failure caused by HBV. The male with HBV-related liver failure was 4.34 times higher than female (cases: 191 vs. 44), which was higher than non-HBV-related liver failure (1.03 times, cases: 68 vs. 66). The 6-month follow-up showed that the proportion of male with HBV-related liver failure who died and survived was significantly higher than that of female (78.76% vs. 21.24% in died patients, 92.86% vs. 7.14% in survival patients, both P < 0.01). The age of died patients in the non-HBV-related liver failure group was significantly higher than that of the survival patients (years: 58.53±0.15 vs. 54.38±3.01, P < 0.05), and the AT III level was significantly lower than that of the survival patients [(32.20±6.43)% vs. (38.63±2.74)%, P < 0.05]. The length of ICU stay of the died HBV-related liver failure group was significantly shorter than that of the survival patients (days: 23.77±11.74 vs. 35.51±2.85, P < 0.01). The 6-month mortality after discharge of HBV-related liver failure combined with liver cancer was significantly higher than that of non-HBV-related liver failure (12.34% vs. 2.24%, P < 0.01), but there was no significant difference in 6-month mortality after discharge of patients receiving artificial liver and those with hepatic encephalopathy and cirrhosis between different types of liver failure groups.

CONCLUSIONS: HBV is the main cause of liver failure. Patients with HBV-related liver failure were younger and had a longer hospitalization period, which was conducive to the recovery of the disease. HBV-related liver failure accompanied with liver cancer is the main factors of death. The AT III has the potential value to reflect the disease outcome.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Yan Y, Lyu C, Ge L, et al. [Etiology and related clinical indicators of liver failure: an analysis of 3-year case data of Wuxi designated hospital for treatment of liver failure]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36567561. doi:10.3760/cma.j.cn121430-20211112-01697

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。